Short answer
Journey Medical Corp (DERM) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Journey Medical announced financial results for the three months ended June 30, 2026.
Journey Medical Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Journey Medical announced financial results for the three months ended June 30, 2026
- Corporate update and detailed results furnished in Exhibit 99.1
- Information furnished under Regulation FD, not filed under Exchange Act Section 18 ответственности
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $18.5M, up 23% year over year, led by Emrosi revenue of $8.1M
- Emrosi prescriptions reached approximately 36,000, up from 30,000 in Q1 2026 and 27,000 in Q4 2025
- GAAP net loss narrowed to $0.3M, or $(0.01) per share, from $3.8M, or $(0.16), year over year
- Adjusted EBITDA turned positive at $2.9M versus $(0.5)M, while gross margin held at 67%
- Cash increased to $25.6M from $24.1M at year-end, supporting continued commercialization and progress toward profitability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Journey Medical Corp 8-K filings
Get the next DERM 8-K as it lands
Follow DERM for push alerts, or ask the research agent what this filing means.